Write notes on liquid based cytology from berek and novak 10 mark answer with proper flowchart,diagrams,easy explanation for final main m.s exam
Reading File
Finding Sources
Finding Sources
Searching the Web
liquid based cytology cervical cancer screening Berek Novak gynecology LBC vs conventional pap smear
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have comprehensive content from Berek & Novak and supplementary sources. Let me compile the comprehensive exam notes with flowcharts and diagrams as ASCII/text-based visual aids.
Liquid-Based Cytology (LBC)
Source: Berek & Novak's Gynecology | 10-Mark MS Final Exam Answer
DEFINITION
Liquid-Based Cytology (LBC) is a thin-layer (monolayer) slide preparation technology introduced as an improved alternative to the conventional Papanicolaou (Pap) smear for cervical cancer screening. Instead of directly smearing cervical cells onto a glass slide, cells are rinsed into a vial of liquid alcohol-based preservative and then processed in the laboratory to produce a uniform, thin layer of cells on a slide.
Berek & Novak: "The ubiquitous use of liquid-based medium to collect the cytologic sample and preserve the collected cervical cells significantly decreased specimen sampling and preparation errors."
HISTORICAL BACKGROUND
| Era | Development |
|---|---|
| 1943 | Papanicolaou introduced conventional Pap smear |
| 1950-2000 | Cervical cancer incidence reduced by 79%, mortality by 70% |
| Late 1990s | LBC introduced (ThinPrep FDA-approved 1996) |
| 2000s | LBC becomes standard in USA; UK NHS adopted LBC nationally |
| Present | HPV co-testing + LBC is current gold standard |
WHY WAS LBC NEEDED? (Limitations of Conventional Pap Smear)
The sensitivity of conventional cytology for detecting CIN 2/3 was only 47-62% with a false-negative rate of 49% (Berek & Novak).
PROBLEMS WITH CONVENTIONAL PAP SMEAR
┌─────────────────────────────────────────────────────┐
│ 1. SAMPLING ERRORS │
│ • Only 10-20% cells transferred to slide │
│ • Small lesions may not exfoliate │
│ │
│ 2. PREPARATION ERRORS │
│ • Air-drying artifact │
│ • Slide too thick │
│ • Obscuring blood, mucus, discharge │
│ │
│ 3. INTERPRETIVE ERRORS │
│ • False-negative rate ~49% │
│ • Observer variability │
└─────────────────────────────────────────────────────┘
↓ LBC SOLVES ALL THREE ↓
STEP-BY-STEP TECHNIQUE (FLOWCHART)
╔══════════════════════════════════════════════════════════╗
║ LIQUID-BASED CYTOLOGY - HOW IT WORKS ║
╠══════════════════════════════════════════════════════════╣
║ ║
║ STEP 1: SPECIMEN COLLECTION ║
║ ┌────────────────────────────────────┐ ║
║ │ Endocervical brush + plastic │ ║
║ │ spatula OR plastic broom device │ ║
║ │ (samples transformation zone) │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 2: RINSING INTO VIAL ║
║ ┌────────────────────────────────────┐ ║
║ │ Device RINSED/SWIRLED in vial │ ║
║ │ containing liquid alcohol-based │ ║
║ │ preservative (NOT smeared) │ ║
║ │ 80-90% cells transferred │ ║
║ │ (vs. 10-20% in conventional Pap) │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 3: LABORATORY PROCESSING ║
║ ┌────────────────────────────────────┐ ║
║ │ Liquid passed through FILTER │ ║
║ │ → Traps larger epithelial cells │ ║
║ │ → Separates small blood cells, │ ║
║ │ inflammatory cells, debris │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 4: SLIDE PREPARATION ║
║ ┌────────────────────────────────────┐ ║
║ │ Uniform THIN MONOLAYER deposited │ ║
║ │ onto glass slide │ ║
║ │ • Clean background │ ║
║ │ • Cells properly preserved │ ║
║ │ • Easy microscopic interpretation │ ║
║ └────────────────┬───────────────────┘ ║
║ ↓ ║
║ STEP 5: REPORTING (Bethesda System) ║
║ ┌────────────────────────────────────┐ ║
║ │ NILM → ASCUS → LSIL → HSIL │ ║
║ │ + Reflex HPV testing possible │ ║
║ └────────────────────────────────────┘ ║
╚══════════════════════════════════════════════════════════╝
TWO FDA-APPROVED COMMERCIAL SYSTEMS
┌──────────────────────────────────────────────────────────┐
│ LBC COMMERCIAL SYSTEMS │
├─────────────────────┬────────────────────────────────────┤
│ ThinPrep® │ SurePath® │
├─────────────────────┼────────────────────────────────────┤
│ Hologic Inc. │ BD Diagnostics │
│ Membrane filter │ Density gradient centrifugation │
│ technique │ technique │
│ FDA approved 1996 │ FDA approved 1999 │
│ Most widely used │ Smaller circle of cells │
│ in USA │ Longer preservation time │
│ Specimen in │ Specimen preserved up to │
│ CytoLyt solution │ 4 weeks │
└─────────────────────┴────────────────────────────────────┘
DIAGRAM: LBC vs CONVENTIONAL PAP SMEAR (Side-by-Side)
CONVENTIONAL PAP SMEAR LIQUID-BASED CYTOLOGY
Cervix → Smear on slide Cervix → Rinse in vial
↓ ↓
Air dry + Fix Lab processing (filter/centrifuge)
↓ ↓
THICK uneven smear THIN uniform monolayer
↓ ↓
Debris/blood obscures Clean clear slide
↓ ↓
10-20% cells transferred 80-90% cells transferred
↓ ↓
Sensitivity: 47-62% Sensitivity: ~81%
Unsatisfactory rate: HIGH Unsatisfactory rate: reduced 70-90%
Reflex HPV: NOT possible Reflex HPV: POSSIBLE from same vial
ADVANTAGES OF LBC (Berek & Novak)
| # | Advantage | Mechanism |
|---|---|---|
| 1 | Reduced unsatisfactory samples | 70-90% reduction; clean background, no debris |
| 2 | Higher cell yield | 80-90% cells transferred vs. 10-20% |
| 3 | Eliminates air drying | Immediate fixation in liquid preservative |
| 4 | No obscuring material | Blood, mucus, inflammation filtered out |
| 5 | Reflex HPV testing | Same vial used for HPV DNA testing (ASCUS triage) |
| 6 | Reduced false-negative rate | Sensitivity improved from ~71% to ~81% |
| 7 | Automated screening | Computer-assisted reading possible |
| 8 | Residual material | Can test for gonorrhea, chlamydia from same vial |
| 9 | Longer preservation | Specimen stable for days to weeks |
| 10 | Uniform cell layer | Easier, faster cytotechnologist review |
DISADVANTAGES OF LBC
┌──────────────────────────────────────────────────────┐
│ DISADVANTAGES OF LBC │
├──────────────────────────────────────────────────────┤
│ • MORE EXPENSIVE than conventional Pap smear │
│ • Cells may ROUND UP → appear smaller │
│ • Nuclei appear more vesicular/delicate │
│ • FEWER LANDMARKS on slide to guide screening │
│ • More time-consuming per unit area to review │
│ • Requires SPECIAL EQUIPMENT in laboratory │
│ • Loss of 3D architecture compared to histology │
│ • Background organisms (Trichomonas) may be harder │
│ to identify │
└──────────────────────────────────────────────────────┘
BETHESDA REPORTING SYSTEM (Used for LBC Results)
┌─────────────────────────────────────────────────────────────┐
│ THE BETHESDA SYSTEM (2014) │
├─────────────────────────────────────────────────────────────┤
│ │
│ NILM ─── Negative for Intraepithelial Lesion/Malignancy │
│ (Normal + infections + non-neoplastic reactive changes) │
│ │
│ OTHER ── Benign endometrial cells in woman ≥45 yrs │
│ │
│ EPITHELIAL CELL ABNORMALITIES: │
│ │
│ SQUAMOUS: │
│ ┌─ ASC-US (Atypical Squamous Cells - Undetermined Sig.) │
│ ├─ ASC-H (Atypical Squamous Cells - cannot exclude HSIL)│
│ ├─ LSIL (Low Grade Squamous Intraepithelial Lesion) │
│ │ = HPV + CIN 1 │
│ ├─ HSIL (High Grade Squamous Intraepithelial Lesion) │
│ │ = CIN 2 + CIN 3 │
│ └─ Squamous Cell Carcinoma │
│ │
│ GLANDULAR: │
│ ├─ AGC (Atypical Glandular Cells) │
│ ├─ AIS (Adenocarcinoma in Situ) │
│ └─ Adenocarcinoma │
└─────────────────────────────────────────────────────────────┘
MANAGEMENT FLOWCHART AFTER LBC RESULT
LBC RESULT
│
┌─────────────┼─────────────┐
↓ ↓ ↓
NILM ASC-US LSIL / HSIL
│ │ │
↓ ↓ ↓
Routine Reflex HPV Colposcopy
Screening Testing + Biopsy
│ │
┌───────┴───────┐ ↓
↓ ↓ Confirm
HPV -ve HPV +ve CIN grade
│ │
↓ ↓
Return to Colposcopy
routine + Biopsy
screening
SCREENING GUIDELINES (Berek & Novak / ACOG)
| Age Group | Recommendation |
|---|---|
| < 21 years | No screening (regardless of sexual debut) |
| 21-29 years | LBC or conventional cytology every 2 years |
| 30-65 years | LBC every 3 years OR LBC + HPV co-test every 5 years |
| > 65 years | Discontinue if 3 consecutive negative results |
| Post-hysterectomy (benign) | Discontinue screening |
| HIV+, Immunocompromised | Twice in year 1, then annually |
| CIN 2+ history | Annually for 20 years |
LBC + HPV CO-TESTING (Current Best Practice)
┌──────────────────────────────────────────────────────┐
│ CO-TESTING STRATEGY (Age ≥30) │
│ │
│ LBC Cytology + HPV DNA Testing (same vial) │
│ │ │
│ ┌────────────┴────────────┐ │
│ ↓ ↓ │
│ Cytology -ve Cytology +ve │
│ HPV -ve OR HPV +ve │
│ │ │ │
│ ↓ ↓ │
│ Screen every 5 yrs Follow guidelines │
│ (very low risk) (colposcopy, etc.) │
└──────────────────────────────────────────────────────┘
High-risk HPV types detected: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
AUTOMATED SCREENING (Adjunct to LBC)
A second FDA-approved technology is the automated image-guided slide screening system:
- Uses automated microscope + digital camera
- Computer algorithms scan every field of view
- Ranks slides by probability of abnormality
- Reduced false-negative rate by 32% (Berek & Novak)
- Cytotechnologist reviews only selected high-risk slides
- Increases throughput and consistency
MICROSOPIC FEATURES OF LBC (What the Pathologist Sees)
NORMAL LBC SLIDE:
┌──────────────────────────────────────┐
│ • Thin, uniform layer of cells │
│ • Clean background (no debris) │
│ • Superficial & intermediate cells │
│ • Small pyknotic nuclei │
│ • Abundant cytoplasm │
│ • No obscuring blood/mucus │
└──────────────────────────────────────┘
ABNORMAL LBC SLIDE (HSIL):
┌──────────────────────────────────────┐
│ • Large cells with enlarged nuclei │
│ • High nuclear:cytoplasmic ratio │
│ • Nuclear hyperchromasia │
│ • Irregular nuclear membrane │
│ • Koilocytes (in LSIL/HPV) │
│ = perinuclear halo + nuclear │
│ hyperchromasia │
└──────────────────────────────────────┘
HIGH-YIELD SUMMARY TABLE (For Quick Revision)
| Parameter | Conventional Pap | LBC |
|---|---|---|
| Cell transfer | 10-20% | 80-90% |
| Sensitivity for CIN 2/3 | 47-62% | ~81% |
| False-negative rate | ~49% | Significantly reduced |
| Unsatisfactory samples | Higher | Reduced 70-90% |
| Air-drying artifact | Common | Eliminated |
| Reflex HPV testing | Not possible | Possible (same vial) |
| Cost | Lower | Higher |
| STI testing (GC/Chlamydia) | No | Yes (same vial) |
| Automated reading | Limited | Yes |
| Background clarity | Often obscured | Clean |
| FDA approved systems | N/A | ThinPrep (1996), SurePath (1999) |
EXAM MEMORY AID
LBC - Remember "FILTER"
┌─────────────────────────────────────────────────┐
│ F - Fixation immediate (no air drying) │
│ I - Increased cell yield (80-90%) │
│ L - Less unsatisfactory specimens (↓70-90%) │
│ T - ThinPrep / SurePath (two main systems) │
│ E - Extra tests possible (HPV, GC, Chlamydia) │
│ R - Reflex HPV testing in ASC-US │
└─────────────────────────────────────────────────┘
10-MARK ANSWER STRUCTURE (MS Final Exam)
Para 1 - Definition + Why needed (2 marks)
Define LBC; state limitations of conventional Pap (49% false-negative, 10-20% cell yield, sampling/preparation/interpretive errors).
Para 2 - Technique with flowchart (2 marks)
Collection device → rinse in vial → filter processing → thin monolayer slide → Bethesda reporting. Two systems: ThinPrep and SurePath.
Para 3 - Advantages (2 marks)
80-90% cell yield; eliminates air-drying; reduces unsatisfactory samples by 70-90%; reflex HPV testing; cleaner background; automated reading possible.
Para 4 - Bethesda System / Reporting (2 marks)
NILM, ASC-US, ASC-H, LSIL (CIN1+HPV), HSIL (CIN2+CIN3), AGC, AIS, carcinoma. Management per result.
Para 5 - Screening guidelines + HPV co-testing (1 mark)
ACOG: screen from age 21; LBC ± HPV per age group. Co-testing every 5 years for 30-65 years.
Para 6 - Disadvantages + Clinical applications (1 mark)
More expensive; cells round up; fewer landmarks; special equipment needed; also used for STI testing from same vial.
Sources: Berek & Novak's Gynecology (16th Ed.), p. 844-846 | Histology: A Text and Atlas | Swanson's Family Medicine Review
What is the recent WHO strategy for elimination of cervical cancer ? What is the role of screening and treatment policy for prevention of it 10 mark answer with flowchart,diagrams and proper easy explanation for m.s main exam from berek and novak
Reading File
Finding Sources
Finding Sources
Searching the Web
WHO 90-70-90 strategy elimination cervical cancer 2030 targets screening treatment
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
WHO cervical cancer elimination strategy VIA VILI LEEP LLETZ colposcopy treatment precancer 2023 2024 guidelines
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive content from Berek & Novak plus WHO strategy details. Let me compile the full 10-mark exam answer:
WHO Strategy for Elimination of Cervical Cancer
Role of Screening and Treatment | 10-Mark MS Final Exam Answer
Source: Berek & Novak's Gynecology + WHO Global Strategy 2020
INTRODUCTION / EPIDEMIOLOGY
Cervical cancer is the 4th most common cancer in women worldwide. It kills one woman every 2 minutes globally. The WHO Global Strategy (launched November 17, 2020) set a bold target: reduce cervical cancer incidence to fewer than 4 cases per 100,000 women per year - the threshold for elimination as a public health problem.
Berek & Novak: "Screening for cervical cancer precursors using exfoliative cervicovaginal cytology was successful in reducing the incidence of cervical cancer by 79% and the mortality by 70% since 1950."
Key facts:
- Annual incidence: ~600,000 new cases globally (2020)
- Annual deaths: ~342,000 (90% in low/middle-income countries)
- Cervical cancer is entirely preventable - caused by persistent high-risk HPV infection
THE WHO 90-70-90 STRATEGY (2020-2030)
╔══════════════════════════════════════════════════════════════════╗
║ WHO GLOBAL STRATEGY - 90-70-90 TARGETS BY 2030 ║
╠════════════════╦═════════════════════════════════════════════════╣
║ 90% ║ Girls fully VACCINATED with HPV vaccine ║
║ (PRIMARY ║ by age 15 years ║
║ PREVENTION) ║ → 9-valent vaccine (Gardasil 9) ║
╠════════════════╬═════════════════════════════════════════════════╣
║ 70% ║ Women SCREENED with a high-performance ║
║ (SECONDARY ║ test by age 35 AND again by age 45 ║
║ PREVENTION) ║ → HPV DNA test preferred ║
╠════════════════╬═════════════════════════════════════════════════╣
║ 90% ║ Women identified with cervical disease ║
║ (TERTIARY ║ receive TREATMENT ║
║ PREVENTION) ║ → 90% pre-cancer treated ║
║ ║ → 90% invasive cancer managed ║
╚════════════════╩═════════════════════════════════════════════════╝
GOAL: < 4 cases / 100,000 women / year
Mathematical impact if 90-70-90 achieved by 2030:
- Cervical cancer deaths averted: 300,000 by 2030; 14 million by 2070; 62 million by 2120
- Incidence fall: 42% by 2045, 97% by 2120
- 74 million new cases of cervical cancer averted
THREE PILLARS OF THE WHO STRATEGY (FLOWCHART)
╔══════════════════════════════════════════════════════════════════════╗
║ THREE PILLARS OF CERVICAL CANCER ELIMINATION ║
╠══════════════════════════════════════════════════════════════════════╣
║ ║
║ PILLAR 1 PILLAR 2 PILLAR 3 ║
║ PRIMARY SECONDARY TERTIARY ║
║ PREVENTION PREVENTION PREVENTION ║
║ ║
║ HPV VACCINATION SCREENING TREATMENT ║
║ ↓ ↓ ↓ ║
║ Girls 9-14 yrs Women 30-49 yrs CIN 2/3 → Ablation/LEEP ║
║ before sexual (twice lifetime) Invasive Ca → Surgery/ ║
║ debut HPV DNA test Chemoradiation ║
║ ↓ ↓ ↓ ║
║ 90% coverage 70% screened 90% treated ║
║ target target target ║
╚══════════════════════════════════════════════════════════════════════╝
PILLAR 1: HPV VACCINATION (PRIMARY PREVENTION)
Available HPV Vaccines
┌─────────────────────────────────────────────────────────────────┐
│ HPV VACCINES COMPARISON │
├────────────────┬──────────────┬────────────────┬───────────────┤
│ VACCINE │ Bivalent │ Quadrivalent │ 9-valent │
│ │ (Cervarix) │ (Gardasil 4) │ (Gardasil 9) │
├────────────────┼──────────────┼────────────────┼───────────────┤
│ Manufacturer │ GSK │ Merck │ Merck │
│ HPV types │ 16, 18 │ 6,11,16,18 │ 6,11,16,18, │
│ covered │ │ │ 31,33,45,52, │
│ │ │ │ 58 │
│ Cancer │ ~70% │ ~70% │ ~90% │
│ protection │ │ │ of all │
│ │ │ │ cervical Ca │
│ Also prevents │ No │ Genital warts │ Genital warts│
│ │ │ │ + anal Ca │
├────────────────┼──────────────┼────────────────┼───────────────┤
│ Status │ Not in US │ Not in US │ CURRENT │
│ │ market │ market │ STANDARD │
└────────────────┴──────────────┴────────────────┴───────────────┘
Vaccination Schedule (Berek & Novak / CDC)
| Age | Schedule | Doses |
|---|---|---|
| 9-14 years (primary target) | 2-dose: 0, 6-12 months | 2 doses |
| 15-26 years | 3-dose: 0, 2, 6 months | 3 doses |
| 27-45 years | Optional (catch-up) | Shared decision-making |
Key Points (Berek & Novak):
- HPV vaccines contain Virus-Like Particles (VLPs) - NOT live virus
- Strongest immune response before sexual debut (prior HPV exposure)
- Vaccinated women must STILL continue cervical screening
- Herd immunity benefit when males also vaccinated
- Australia: 70% coverage → genital warts nearly disappeared in <21 yrs
- No therapeutic efficacy against pre-existing HPV infection
PILLAR 2: SCREENING (SECONDARY PREVENTION)
Screening Methods Available
┌──────────────────────────────────────────────────────────────────┐
│ CERVICAL CANCER SCREENING TESTS │
├──────────────────────────┬───────────────────────────────────────┤
│ TEST │ FEATURES │
├──────────────────────────┼───────────────────────────────────────┤
│ Conventional Pap Smear │ Sensitivity 47-62% for CIN 2/3 │
│ │ False-negative rate 49% │
│ │ Low cost, widely available │
├──────────────────────────┼───────────────────────────────────────┤
│ Liquid-Based Cytology │ Sensitivity ~81% │
│ (ThinPrep / SurePath) │ Reflex HPV testing possible │
│ │ Unsatisfactory rates ↓70-90% │
├──────────────────────────┼───────────────────────────────────────┤
│ HPV DNA Testing │ Highest sensitivity (>95%) │
│ (PRIMARY SCREEN) │ WHO preferred for women 30-65 │
│ │ Detects high-risk HPV types 16/18+ │
├──────────────────────────┼───────────────────────────────────────┤
│ VIA (Visual Inspection │ Acetic acid applied to cervix │
│ with Acetic Acid) │ White areas = acetowhite = abnormal │
│ │ Low-resource settings; immediate │
│ │ "see and treat" approach │
├──────────────────────────┼───────────────────────────────────────┤
│ VILI (Visual Inspection │ Lugol's iodine applied │
│ with Lugol's Iodine) │ Abnormal = mustard/saffron yellow │
│ │ Normal = mahogany brown │
└──────────────────────────┴───────────────────────────────────────┘
WHO-Recommended Screening Algorithm (Flowchart)
ALL WOMEN 30-49 YEARS
│
↓
┌─── HPV DNA TEST (1st choice) ───┐
│ OR Cytology / VIA │
└──────────────────────────────────┘
│
┌──────────────┴──────────────┐
↓ ↓
HPV NEGATIVE HPV POSITIVE
│ │
↓ ↓
Rescreen in 5 years TRIAGE (Colposcopy /
(2nd screen at age 45) Cytology / VIA)
│
┌─────────────────┴──────────────┐
↓ ↓
NO CIN / CIN 1 CIN 2 / CIN 3
│ │
↓ ↓
Follow-up / Repeat TREATMENT
in 1-3 years (Ablation or LEEP)
ACOG Screening Guidelines (Berek & Novak)
| Age | Recommended Test | Frequency |
|---|---|---|
| < 21 years | No screening | - |
| 21-29 years | Cytology alone | Every 3 years |
| 30-65 years | Co-test (LBC + HPV) | Every 5 years (preferred) |
| 30-65 years | Cytology alone | Every 3 years (acceptable) |
| 30-65 years | Primary HPV testing | Every 5 years (USPSTF) |
| > 65 years | Discontinue | If 3 consecutive negative cytology or 2 negative co-tests in 10 years |
| Post-hysterectomy (benign) | Discontinue | - |
| HIV+/Immunocompromised | Cytology | 2x in year 1, then annually |
| CIN 2+ history | Annual | For 20 years |
PILLAR 3: TREATMENT (TERTIARY PREVENTION)
A. Treatment of Pre-Cancer (CIN)
┌──────────────────────────────────────────────────────────────────┐
│ CIN GRADING AND TREATMENT ALGORITHM │
│ │
│ HISTOLOGY RESULT │
│ │ │
│ ┌────┴────────────────────────────────────┐ │
│ ↓ ↓ ↓ │
│ CIN 1 CIN 2 CIN 3 │
│ │ │ │ │
│ ↓ ↓ ↓ │
│ HPV/LSIL HSIL HSIL │
│ Surveillance TREAT TREAT │
│ 12-24 months ↓ ↓ │
│ (>60% regress) ABLATIVE EXCISIONAL │
│ (if eligible) (preferred) │
│ or ───────────── │
│ EXCISIONAL • LEEP / LLETZ │
│ • Cold Knife Conization │
│ • Laser conization │
└──────────────────────────────────────────────────────────────────┘
Treatment Methods Compared
┌─────────────────────────────────────────────────────────────────────┐
│ TREATMENT MODALITIES FOR CERVICAL PRE-CANCER │
├──────────────────────┬──────────────────────────────────────────────┤
│ ABLATIVE METHODS │ EXCISIONAL METHODS │
│ (Destroys tissue) │ (Removes tissue - preferred) │
├──────────────────────┼──────────────────────────────────────────────┤
│ • Cryotherapy │ • LEEP (Loop Electrosurgical Excision Proc) │
│ • Laser ablation │ = LLETZ (Large Loop Excision Transform. │
│ • Thermal ablation │ Zone) - PREFERRED (Berek & Novak) │
│ • Cold coagulation │ • Cold Knife Conization (CKC) │
├──────────────────────┼──────────────────────────────────────────────┤
│ ELIGIBILITY: │ WHEN EXCISION IS MANDATORY: │
│ • Lesion visible │ • Suspected microinvasive/invasive cancer │
│ • Lesion in TZ │ • Inadequate colposcopy │
│ • No suspicion of │ • Positive ECC │
│ invasion │ • AIS on biopsy │
│ • No pregnancy │ • Ablation failed │
├──────────────────────┼──────────────────────────────────────────────┤
│ Cure rate: ~85-90% │ Cure rate: ~90-95% │
└──────────────────────┴──────────────────────────────────────────────┘
LEEP/LLETZ (Preferred Treatment - Berek & Novak Key Point #15):
"Although CIN 2 and CIN 3 can be treated with a variety of outpatient techniques, the preferred treatment is LEEP. Ablative therapy...is not appropriate if there is evidence of microinvasive or invasive cancer on cytology, colposcopy, endocervical curettage or biopsy."
AIS Treatment (Berek & Novak Key Point #16):
"The preferred management for women who have completed childbearing with histologic diagnosis of AIS is hysterectomy."
B. Treatment of Invasive Cervical Cancer
┌─────────────────────────────────────────────────────────────────┐
│ TREATMENT OF INVASIVE CERVICAL CANCER │
├──────────────────────┬──────────────────────────────────────────┤
│ EARLY STAGE │ ADVANCED STAGE │
│ (IA1, IA2, IB1) │ (IB2, IIA, IIB, III, IV) │
├──────────────────────┼──────────────────────────────────────────┤
│ • Radical │ • Concurrent Chemo-Radiation │
│ Hysterectomy + │ (Cisplatin-based + Radiation) │
│ Pelvic LN │ • External beam + Brachytherapy │
│ dissection │ • Immunotherapy (Pembrolizumab - │
│ OR │ recurrent/metastatic disease) │
│ • Radiation alone │ • Bevacizumab (anti-VEGF) │
│ (for unfit pts) │ │
├──────────────────────┼──────────────────────────────────────────┤
│ For fertility: │ Recurrent disease: │
│ • Radical │ • Pelvic exenteration │
│ trachelectomy │ • Palliative chemotherapy │
│ (IA2, IB1 <2cm) │ │
└──────────────────────┴──────────────────────────────────────────┘
COMPLETE PATHWAY: PREVENTION TO TREATMENT (MASTER FLOWCHART)
╔══════════════════════════════════════════════════════════════════════════╗
║ COMPLETE WHO CERVICAL CANCER ELIMINATION PATHWAY ║
╠══════════════════════════════════════════════════════════════════════════╣
║ ║
║ FEMALE CHILD (9-14 yrs) ║
║ │ ║
║ ↓ ║
║ HPV VACCINATION (Gardasil 9: 2-dose regimen) ║
║ [90% target] Covers HPV 6,11,16,18,31,33,45,52,58 ║
║ │ ║
║ ADOLESCENT/ADULT WOMAN (21+ years) ║
║ │ ║
║ ↓ ║
║ CERVICAL CANCER SCREENING ║
║ Age 21-29: Cytology every 3 years [70% target] ║
║ Age 30-65: HPV DNA + LBC co-test every 5 years (preferred) ║
║ │ ║
║ ┌────┴────────────┐ ║
║ ↓ ↓ ║
║ NEGATIVE POSITIVE ║
║ │ │ ║
║ Routine Colposcopy + Biopsy ║
║ Screening │ ║
║ ┌────┴──────────────────────┐ ║
║ ↓ ↓ ║
║ CIN 1 CIN 2 / CIN 3 ║
║ │ │ ║
║ Surveillance TREATMENT ║
║ (60% regress) [90% target] ║
║ ┌────────────────┐ ║
║ ↓ ↓ ║
║ ABLATION LEEP/LLETZ ║
║ (if eligible) (PREFERRED) ║
║ │ │ ║
║ └────────────────┘ ║
║ │ ║
║ POST-TREATMENT ║
║ SURVEILLANCE ║
║ │ ║
║ ┌───────────────┴──────────────┐ ║
║ ↓ ↓ ║
║ CLEAR/CURED INVASIVE CANCER ║
║ Rescreen in ↓ ║
║ 3-5 years Surgery / Chemo-RT ║
║ / Immunotherapy ║
╚══════════════════════════════════════════════════════════════════════════╝
SCREEN-AND-TREAT APPROACH (Low-Resource Settings)
For low/middle-income countries (WHO recommendation):
┌──────────────────────────────────────────────────────────────────┐
│ SCREEN-AND-TREAT ALGORITHM (WHO 2021) │
│ │
│ SCREEN WITH: POSITIVE TREAT IMMEDIATELY │
│ VIA / HPV test ──────────────→ (Same visit if VIA+) │
│ │
│ VIA POSITIVE → Thermal ablation (same visit) OR LEEP │
│ HPV+ + VIA+ → Thermal ablation or LEEP │
│ HPV+ + VIA- → Colposcopy/cytology triage before treat │
│ │
│ ADVANTAGE: Single visit - reduces loss to follow-up │
│ Especially useful in resource-limited settings │
└──────────────────────────────────────────────────────────────────┘
ASC-US TRIAGE FLOWCHART (ALTS Trial - Berek & Novak)
ASC-US ON CYTOLOGY
│
┌────────────┼────────────────┐
↓ ↓ ↓
Immediate HPV Reflex Repeat Pap
Colposcopy Testing in 6 months
(most (PREFERRED) (least sensitive)
sensitive) │
┌────┴────┐
↓ ↓
HPV -ve HPV +ve
│ │
↓ ↓
Routine Colposcopy
Screen (Sensitivity 96%
for CIN 2/3)
ALTS Trial Key Data (Berek & Novak):
- HPV test sensitivity for CIN 2: 95.9%
- HPV test sensitivity for CIN 3: 96.3%
- 80% of ASC-US women have NO significant lesion on colposcopy
CERVICAL CARCINOGENESIS (Understanding the Biology)
NORMAL CERVIX
↓ (HPV 16/18 infection - 50× ↑ risk)
HPV INFECTION (clears in 80% within 2 years)
↓ (10-20% persist → risk factor: smoking, immunosuppression, OCP)
CIN 1 (LSIL) → 60% spontaneous regression
↓
CIN 2 (HSIL) → 40% regression, 20% progress
↓
CIN 3 (HSIL) → Carcinoma in situ
↓ (average 10-15 years)
INVASIVE CARCINOMA
Risk Factors (Berek & Novak):
- HPV types 16/18 → 50-fold increased risk for precancerous lesions
- Early sexual debut + multiple partners
- Immunosuppression (HIV: screen twice/year 1, then annually)
- Smoking
- Long-term OCP use (RR 2.2 at >10 years)
- Lack of screening (>50% invasive cancer in never-screened women)
IMPACT OF 90-70-90 STRATEGY (Summary Diagram)
┌─────────────────────────────────────────────────────────────────┐
│ PROJECTED IMPACT IF 90-70-90 TARGETS MET BY 2030 │
├────────────────────────┬────────────────────────────────────────┤
│ Timeline │ Benefit │
├────────────────────────┼────────────────────────────────────────┤
│ By 2030 │ 300,000 deaths averted │
│ By 2045 │ 42% fall in incidence │
│ By 2070 │ 14 million deaths averted │
│ By 2120 │ 97% fall in incidence │
│ │ 62 million deaths averted │
│ │ 74 million new cases averted │
├────────────────────────┼────────────────────────────────────────┤
│ Also contributes to: │ SDG 1 (poverty elimination), │
│ │ SDG 3 (health & well-being), │
│ │ SDG 5 (gender equality) │
└────────────────────────┴────────────────────────────────────────┘
HIGH-YIELD KEY POINTS (Quick Revision)
| # | Point |
|---|---|
| 1 | WHO 90-70-90 launched November 2020; goal: <4 cases/100,000/year |
| 2 | Three pillars: Vaccination → Screening → Treatment |
| 3 | Gardasil 9 covers 9 HPV types → ~90% of cervical cancers |
| 4 | HPV vaccines are VLPs - NOT live virus; NO therapeutic effect on existing HPV |
| 5 | Vaccinate GIRLS before sexual debut (age 9-14); 2-dose regimen |
| 6 | Screen women TWICE: at age 35 AND age 45 (minimum WHO recommendation) |
| 7 | HPV DNA test is the preferred primary screening modality (highest sensitivity >95%) |
| 8 | LEEP/LLETZ is the preferred treatment for CIN 2/3 (Berek & Novak) |
| 9 | CIN 1 = surveillance; CIN 2/3 = active treatment (not watchful waiting) |
| 10 | AIS → hysterectomy (preferred after completing childbearing) |
| 11 | Screen-and-treat (VIA + same-visit ablation) for low-resource countries |
| 12 | ASC-US → Reflex HPV testing; HPV+ → colposcopy |
EXAM MEMORY AID
WHO 90-70-90 = "VaccScreen-Treat"
┌──────────────────────────────────────────────────────┐
│ 90% Vaccinated → Girls age 9-14, Gardasil 9 │
│ 70% Screened → Women 35+45 yrs, HPV DNA test │
│ 90% Treated → CIN2/3 → LEEP; Invasive → Surgery│
│ │
│ TARGET: < 4/100,000/year = ELIMINATION │
└──────────────────────────────────────────────────────┘
10-MARK ANSWER STRUCTURE
Para 1 - Introduction + WHO global burden (1 mark): 4th most common cancer; 600,000/year; one death every 2 minutes; 90% in LMICs; entirely preventable.
Para 2 - WHO 90-70-90 strategy + definition of elimination (2 marks): Launched 2020; three targets by 2030; elimination = <4/100,000/year; projected 62 million deaths averted.
Para 3 - Pillar 1: Vaccination (2 marks): Gardasil 9 (9-valent VLP vaccine); HPV types covered; 2-dose/3-dose schedules; VIA analogy; must continue screening after vaccination.
Para 4 - Pillar 2: Screening (2 marks): Methods (VIA/VILI/Cytology/LBC/HPV DNA); ACOG guidelines table; HPV DNA as primary screen; co-testing; ASC-US triage with ALTS trial data.
Para 5 - Pillar 3: Treatment (2 marks): CIN grading; ablative vs. excisional methods; LEEP as preferred (Berek & Novak); AIS → hysterectomy; invasive cancer → stage-based management; screen-and-treat for LMICs.
Para 6 - Impact + Conclusion (1 mark): Projected impact statistics; SDG goals; "Only cancer for which we have all three primary/secondary/tertiary prevention tools."
Sources: Berek & Novak's Gynecology (16th Ed.), Chapter 16, pp. 833-848 | WHO Global Strategy to Accelerate the Elimination of Cervical Cancer (2020) | Dermatology 5e (Gardasil 9 section) | WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions (2021 update)
This is a shared conversation. Sign in to Orris to start your own chat.